T2D plasma exosomes require BRD4 to upregulate EMT genes and PD
T2D plasma exosomes require BRD4 to upregulate EMT genes and PD-L1 expression. (A) Expression of SNAI1 and CD274 genes in DU145 cells measured by RT-PCR of cellular RNA after exosome treatment.

T2D plasma exosomes require BRD4 to upregulate EMT genes and PD-L1 expression. (A) Expression of SNAI1 and CD274 genes in DU145 cells measured by RT-PCR of cellular RNA after exosome treatment.
PDF Novel plasma exosome biomarkers for prostate cancer ...

T2D plasma exosomes require BRD4 to upregulate EMT genes and PD-L1 expression. (A) Expression of SNAI1 and CD274 genes in DU145 cells measured by RT-PCR of cellular RNA after exosome treatment.
T2D plasma exosomes require BRD4 to upregulate EMT genes and PD-L1 expression. (A) Expression of SNAI1 and CD274 genes in DU145 cells measured by RT-PCR of cellular RNA after exosome treatment.
PDF Novel plasma exosome biomarkers for prostate cancer ...
T2D plasma exosomes require BRD4 to upregulate EMT genes and PD-L1 expression. (A) Expression ofSNAI1and CD274genes in DU145 cells measured by RT-PCR of cellular RNA after exosome treatment.
We build on our previous reports showing BRD4 controls migration and dissemination of castration-resistant prostate cancer, and transcription of key EMT genes , to show that T2D exosomes require BRD4 to drive EMT and immune ligand expression.

Novel plasma exosome biomarkers for prostate cancer progression in co ...
Here, we hypothesized that T2D plasma exosomes induce epithelial-mesenchymal transition ( EMT ) and immune checkpoints in prostate cancer cells. We demonstrate that plasma exosomes from subjects with T2D induce EMT features in prostate cancer cells and upregulate the checkpoint genes CD274 and CD155.
The findings suggest a new signaling map linking the pro- EMT effect of T2D plasma exosomes with PD-L1 expression through BRD4 . Specific plasma exosomal miRNAs could be useful as non-invasive clinical biomarkers, and they ...





